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Introduction
Igeneon is currently testing a humanized monoclonal
antibody specific for Lewis Y (IGN311) in clinical trials of
passive cancer immunotherapy. The aim of the current
study is to enhance the effector function of this antibody
by genetically modifying the antibody producing cell line
to express the glycosyl transferase GnTIII. The presence of
this enzyme leads to glycosylation of the antibody with a
bi-secting N-acetyl-glucosamine group and the absence of
core fucosylation.
Methods
First, heavy and light chain genes of IGN311 were iso-
lated, cloned into an expression vector and transfected
transiently into EBNA cells: Genes for GnTIII tranferase
expression were co-transfected resulting in a new expres-
sion product; an antibody, now called IGN312, with
modified N-glycosylation pattern. A control wild-type
antibody IGN311 wt. was expressed using exactly the
same expression vectors and the same host but without
co-transfection of genes for GnTIII expression. Both
expression products were purified to homogeneity using
an identical protein-A based down stream process. Expres-
sion products were characterized by SDS-PAGE, IEF and a
target antigen specific sandwich ELISA.
Results
No degradation products could be detected and target
affinity of the glyco-engineered antibody as well as assem-
bling of heavy and light chains was not affected by GnTIII
expression. In vitro experiments showed an up to 25 fold
increased ADCC lysis activity of the glyco-engineered anti-
body IGN312 in comparison to the wild type expression
product using six Lewis Y positive target cancer cell lines
(SKBR5, SKBR3, LoVo, MCF7, OVCAR3 and Kato III).
However, CDC activity measured on SKBR5 target cell line
was 40% reduced. The reduction of CDC activity could be
prevented by using a slightly different molecular-biologi-
cal approach for increased levels of complex N-linked oli-
gosaccharides of bisected, non-fucosylated type. With this
approach, it could be shown to increase ADCC activity
without reducing CDC activity. In fact, in this particular
case the CDC activity was even 2- fold enhanced. Binding
activity for this second-generation glyco-engineered anti-
body measured by specific sandwich ELISA was not
affected.
Conclusions
Next steps will be the generation of a stable IGN312
expressing cell line that produces an antibody with
enhanced effector functions. The long term medical and
economical goal will be that, due to the enhanced potency
of IGN312, the minimal effective dose needed for success-
ful treatment of patients with epithelial Lewis Y express-
ing, cancers can be reduced significantly.
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